C. Tacquard, W. Oulehri, O. Collange, L. H. Garvey, S. Nicoll, N. Tuzin, B. Gény, P. Mertes
{"title":"在致死性过敏性休克的啮齿动物模型中,血小板活化因子受体拮抗剂治疗可改善血流动力学并降低肾上腺素需求","authors":"C. Tacquard, W. Oulehri, O. Collange, L. H. Garvey, S. Nicoll, N. Tuzin, B. Gény, P. Mertes","doi":"10.1111/cea.13540","DOIUrl":null,"url":null,"abstract":"In some cases, anaphylactic shock (AS) is still lethal, despite rapid use of epinephrine. High doses of epinephrine are associated with severe complications. Platelet‐activating factor (PAF) is secreted in massive amounts during AS, and a high plasma level is correlated with increased AS severity.","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"33 1","pages":"383 - 390"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":"{\"title\":\"Treatment with a platelet‐activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock\",\"authors\":\"C. Tacquard, W. Oulehri, O. Collange, L. H. Garvey, S. Nicoll, N. Tuzin, B. Gény, P. Mertes\",\"doi\":\"10.1111/cea.13540\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In some cases, anaphylactic shock (AS) is still lethal, despite rapid use of epinephrine. High doses of epinephrine are associated with severe complications. Platelet‐activating factor (PAF) is secreted in massive amounts during AS, and a high plasma level is correlated with increased AS severity.\",\"PeriodicalId\":10148,\"journal\":{\"name\":\"Clinical & Experimental Allergy\",\"volume\":\"33 1\",\"pages\":\"383 - 390\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Experimental Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/cea.13540\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Experimental Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/cea.13540","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment with a platelet‐activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock
In some cases, anaphylactic shock (AS) is still lethal, despite rapid use of epinephrine. High doses of epinephrine are associated with severe complications. Platelet‐activating factor (PAF) is secreted in massive amounts during AS, and a high plasma level is correlated with increased AS severity.